Baidu
map

Sci Transl Med:心脏病药物将癌细胞转化为疫苗

2012-07-25 ZinFingerNase 生物谷

根据一项于2012年7月18日发表在Science Translational Medicine期刊上的研究,一类被称作强心苷(cardiac glycosides)的心脏病药物能够诱导免疫原性细胞死亡(immunogenic cell death, ICD),并以此将死亡的癌细胞转化为一种刺激抗肿瘤反应的疫苗。 来自法国国家健康与医学研究院的Laurie Menger和同事们开发出并利用一种基

根据一项于2012年7月18日发表在Science Translational Medicine期刊上的研究,一类被称作强心苷(cardiac glycosides)的心脏病药物能够诱导免疫原性细胞死亡(immunogenic cell death, ICD),并以此将死亡的癌细胞转化为一种刺激抗肿瘤反应的疫苗。

来自法国国家健康与医学研究院的Laurie Menger和同事们开发出并利用一种基于自动化表面荧光显微技术(epifluorescence microscopy)的平台来鉴定免疫原性细胞死亡(ICD)的诱导剂。

研究人员发现强心苷是一类强效的ICD诱导剂,而且这种效果与抑制细胞膜中的钠钾依赖性三磷酸腺苷酶相关联。在具有免疫能力的小鼠体内,它们的抗癌效果只有与DNA损伤性试剂一起使用时才能够看得到。经过化疗药物和强心苷处理过的癌细胞能有效地作为经过活的同类型癌细胞激发的小鼠的疫苗。此外,对145名接受强心苷治疗的癌症患者和290名没有接受强心苷治疗的癌症患者进行的一项回顾性分析表明接受强心苷治疗的患者5年存活率得到改善(风险比为0.62)。

Menger和同事们写道,“确定一大类细胞毒性试剂拥有诱导ICD的能力将是令人感兴趣的,因此这有助于人们鉴定出引发一种免疫学上旁观者效应(bystander effect)的新药物。再者,在药物开发生产线中,基于它们促进ICD的能力,人们也可能明智地决定在临床上开发出拥有相同靶标和作物机制的化合物。”

本文编译自Heart medication converts cancer cells into vaccine

doi: 10.1126/scitranslmed.3003807
PMC:
PMID:

Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death

Laurie Menger1,2,3, Erika Vacchelli1,2,3, Sandy Adjemian et al.

Some successful chemotherapeutics, notably anthracyclines and oxaliplatin, induce a type of cell stress and death that is immunogenic, hence converting the patient’s dying cancer cells into a vaccine that stimulates antitumor immune responses. By means of a fluorescence microscopy platform that allows for the automated detection of the biochemical hallmarks of such a peculiar cell death modality, we identified cardiac glycosides (CGs) as exceptionally efficient inducers of immunogenic cell death, an effect that was associated with the inhibition of the plasma membrane Na+- and K+-dependent adenosine triphosphatase (Na+/K+-ATPase). CGs exacerbated the antineoplastic effects of DNA-damaging agents in immunocompetent but not immunodeficient mice. Moreover, cancer cells succumbing to a combination of chemotherapy plus CGs could vaccinate syngeneic mice against a subsequent challenge with living cells of the same type. Finally, retrospective clinical analyses revealed that the administration of the CG digoxin during chemotherapy had a positive impact on overall survival in cohorts of breast, colorectal, head and neck, and hepatocellular carcinoma patients, especially when they were treated with agents other than anthracyclines and oxaliplatin.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2067104, encodeId=bb47206e104c4, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Nov 07 20:12:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656543, encodeId=28ae1656543da, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu May 30 23:12:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251903, encodeId=bf9c1251903d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605793, encodeId=e05e1605e9301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2067104, encodeId=bb47206e104c4, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Nov 07 20:12:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656543, encodeId=28ae1656543da, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu May 30 23:12:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251903, encodeId=bf9c1251903d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605793, encodeId=e05e1605e9301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2013-05-30 bsmagic9140
  3. [GetPortalCommentsPageByObjectIdResponse(id=2067104, encodeId=bb47206e104c4, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Nov 07 20:12:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656543, encodeId=28ae1656543da, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu May 30 23:12:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251903, encodeId=bf9c1251903d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605793, encodeId=e05e1605e9301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]
    2012-07-27 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=2067104, encodeId=bb47206e104c4, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Wed Nov 07 20:12:00 CST 2012, time=2012-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656543, encodeId=28ae1656543da, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu May 30 23:12:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251903, encodeId=bf9c1251903d2, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605793, encodeId=e05e1605e9301, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 27 06:12:00 CST 2012, time=2012-07-27, status=1, ipAttribution=)]

相关资讯

AACE 2012:Resolute支架在糖尿病患者中的性能优

   在第21届美国临床内分泌医师协会年会(AACE2012, 5月23~27日, 美国费城)提交的一项新研究报告称,非胰岛素依赖型糖尿病患者置入Resolute佐他莫司洗脱冠脉支架2年后的安全性和功能预后与置入该支架的非糖尿病患者相似。此外,置入Resolute支架的胰岛素依赖型糖尿病患者的预后优于文献报道的置入其他药物洗脱支架(DES)的糖尿病患者。   今年3月,美国食品药品管理

PLoS One:降压/降脂复合制剂降低卒中和心脏病风险

   英国伦敦大学玛丽女王学院的研究人员在新一期PLoS One(《科学公共图书馆综合卷》)杂志上报告说,他们将氨氯地平、氯沙坦、氢氯噻嗪这三种降压药物和辛伐他汀这种降胆固醇药物混合在一起制成复合制剂,并以80多名50岁以上的中老年人为对象进行了随机对比试验。        结果显示,这种复合制剂可以使服药者血压平均降低12

PLoS Med:荟萃分析确认BMI与心脏病的风险关系

(图片来源:Medpage Today) 英国布里斯托大学的Nicholas J. Timpson博士等人近日在《公共科学图书馆·医学》(PLoS Medicine)杂志发表论文称,身体质量指数(BMI)升高可增大发生缺血性心脏病的风险。 研究者称,如果将遗传因素考虑进去,BMI每升高4 kg/m2 ,发生缺血性心脏病的风险将增大52%(95%可信区间为1.12至2.05)。 之前已有多项观

AJCN:食用橄榄油可降心脏病死亡风险

不少人知道,橄榄油有益心脏健康,那么到底有什么益处?西班牙研究人员发现,一天食用两汤勺即大约30克橄榄油能降低因心脏病而亡风险近一半。   护心脏   西班牙研究人员分析了40622名西班牙居民的数据。这些居民都于1992年至1993年参加欧洲癌症与营养前瞻性调查,参与时年龄为29岁至69岁。这项调查主要了解参与者日常饮食情况,包括橄榄油摄入量和热量摄取。  

非手术中心无保护左主干病变PCI安全有效

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上公布的英国学者的一项研究表明:在高容量非手术中心,所有年龄组病人的无保护左主干冠脉(ULMCA)经皮冠脉介入(PCI)治疗成功率高,死亡率低;尽管1/4的病人采用了2个支架策略,进行了积极的冠脉血管造影(IVUS)随访,但靶血管血运重建(TVR)仍很低。在上述病人队列中,ULMCA PCI不但安全而且有效。PCI是高龄

巴西长达7年全国性队列研究:PTCA对比CABG

  2012年世界心脏病学大会于4月18~21日在阿联酋迪拜召开,会上公布了巴西学者在冠脉血运重建病人中开展的一项比较经皮冠状动脉腔内成形术(PTCA)和冠状动脉旁路移植术(CABG)对冠状动脉疾病病人的临床益处的全国性队列研究。该研究果显示:年龄和CABG而非性别与预后独立相关。   目前经皮冠状动脉腔内成形术(PTCA)相较于CABG对冠状动脉疾病病人的临床益处。这项研究旨在评估PTCA或C

Baidu
map
Baidu
map
Baidu
map